Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
bemarituzumab
×
Gastrointestinal
×
Clear all
Filters
3
NCT03343301
2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 1
Completed
12 enrolled
17 charts